# US 2015/0147352 A1 · Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147352 A1
- Document ID: US20150147352A1
- Status: Published application
- Kind: A1
- Application number: 14/412,191
- Filed: 2013-07-03
- Published: 2015-05-28
- Earliest claimed: 2012-07-05
- Assignees: Nutramax Laboratories, Inc.
- Applicants: Nutramax Laboratories, Inc.
- Inventors: Brian Cornblatt; Grace Cornblatt; Anton Bzhelyansky; Robert Henderson
- Web page: https://patentgrep.com/patent/US20150147352A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K 31/716: Glucans
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 36/06: Fungi, e.g. yeasts
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/31: Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 3/06: Antihyperlipidemics
- C12Y 302/01147: Thioglucosidase (3.2.1.147), i.e. myrosinase
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The invention also relates to the combination of sulforaphane or a derivative thereof and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present invention also relates to the combination of a broccoli extract or powder and a mushroom (preferably maitake, shiitake, or reishi mushroom) extract or powder. The present provides compositions and methods relating to these combinations.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

An orally administrable composition comprising a broccoli extract or powder and a mushroom extract or powder.

### Claim 23 (depends on 22)

The orally administrable composition of claim 22, wherein the broccoli extract or powder comprises glucoraphanin in an amount of about 1 to about 75% w/w.

### Claim 24 (depends on 22)

The orally administrable composition of claim 22, wherein the broccoli extract or powder comprises myrosinase.

### Claim 25 (depends on 22)

The orally administrable composition of claim 22, further comprising an enzyme potentiator.

### Claim 26 (depends on 22)

The orally administration composition of claim 22, wherein the enzyme potentiator comprises ascorbic acid.

### Claim 27 (depends on 22)

The orally administrable composition of claim 22, wherein the composition comprises an enteric dosage form.

### Claim 28 (depends on 22)

The orally administrable composition of claim 22, wherein the mushroom extract or powder comprises one or more mushroom extracts or powders selected from the group of: maitake mushroom extract, shiitake mushroom extract, and reishi mushroom extract.

### Claim 29 (depends on 22)

The orally administrable composition of claim 22, comprising a maitake mushroom extract comprising one or more glucans.

### Claim 30 (depends on 22)

The orally administrable composition of claim 22, comprising a maitake mushroom extract comprising beta-glucan.

### Claim 31 (depends on 22)

The orally administrable composition of claim 22, comprising a shiitake mushroom extract comprising one or more glucans.

### Claim 32 (depends on 22)

The orally administrable composition of claim 22, comprising a shiitake mushroom extract comprising alpha-glucan.

### Claim 33 (depends on 22)

The orally administrable composition of claim 22, comprising a reishi mushroom extract comprising one or more glucans.

### Claim 34 (depends on 22)

The orally administrable composition of claim 22, comprising a reishi mushroom extract comprising beta-glucan.

### Claim 35 (depends on 22)

The orally administrable composition of claim 22, comprising a maitake mushroom extract and a shiitake mushroom extract.

### Claim 36 (depends on 22)

A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and reducing secondary recurrences of breast cancer, prostate cancer, colon cancer, lung cancer, and bladder cancer, comprising administering to a subject in need thereof the orally administrable composition of claim 22.

### Claim 37 (depends on 22)

A method of increasing levels or increasing gene expression of NAD(P)H:quinone oxidoreductase 1 (NQO-1) in a subject in need thereof, comprising administering to the subject in need thereof the orally administrable composition of claim 22.

### Claim 38 (depends on 22)

A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of quinone estrogen in a subject in need thereof, comprising administering to the subject in need thereof the orally administrable composition of claim 22.

### Claim 39

An orally administrable composition comprising sulforaphane or a derivative thereof and a mushroom extract or powder.

### Claim 40 (depends on 39)

The orally administrable composition of claim 39, comprising a maitake mushroom extract comprising one or more glucans.

### Claim 41 (depends on 39)

The orally administrable composition of claim 39, comprising a maitake mushroom extract comprising beta-glucan.

### Claim 42 (depends on 39)

The orally administrable composition of claim 39, comprising a shiitake mushroom extract comprising one or more glucans.

### Claim 43 (depends on 39)

The orally administrable composition of claim 39, comprising a shiitake mushroom extract comprising alpha-glucan.

### Claim 44 (depends on 39)

The orally administrable composition of claim 39, comprising a maitake mushroom extract comprising one or more glucans.

### Claim 45 (depends on 39)

The orally administrable composition of claim 39, comprising a maitake mushroom extract comprising beta-glucan.

### Claim 46 (depends on 39)

The orally administrable composition of claim 39, comprising a maitake mushroom extract and a shiitake mushroom extract.

### Claim 47 (depends on 39)

The orally administrable composition of claim 39, wherein the one or more additional components is selected from the group consisting of: quercetin, an aminosugar, a glycosaminoglycan, avocado/soybean unsaponifiable, a vitamin, coffee fruit, magnesium, silymarin, proanthocyanidins, ursolic acid, curcumin, phytosterols, and phytostanols.

### Claim 48 (depends on 39)

A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of breast cancer, prostate cancer, colon cancer, lung cancer, and bladder cancer in a subject in need thereof, comprising administering to the orally administrable composition of claim 39.

### Claim 49 (depends on 39)

A method of increasing levels or increasing gene expression of NAD(P)H:quinone oxidoreductase 1 (NQO-1) in a subject in need thereof, comprising administering to the subject the orally administrable composition of claim 39.

### Claim 50 (depends on 39)

A method of treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of a disease or condition associated with elevated levels of quinone estrogen in a subject in need thereof, comprising administering to the subject the orally administrable composition of claim 39.